Patents by Inventor Xiaoyuan Chen

Xiaoyuan Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11992536
    Abstract: The present disclosure relates to the fields of nuclear medicine and molecular imaging, and specifically relates to a dual-targeting compound and a preparation method and application thereof. The dual-targeting compound has the following structure shown in Formula (I). The present disclosure also provides a dual-targeting compound capable of being labeled with a radionuclide, and the compound has the following structure shown in Formula (I-1) or Formula (1-2). The dual-targeting compound of the present disclosure has high affinity for an FAP target and an integrin ?v?3 target, can realize synergistic targeting of the FAP target and the integrin ?v?3 target in tumors, and has high uptake in tumors and long retention time in tumors.
    Type: Grant
    Filed: December 9, 2022
    Date of Patent: May 28, 2024
    Assignee: YANTAI LANNACHENG BIOTECHNOLOGY CO., LTD.
    Inventors: Xiaoyuan Chen, Pengfei Xu, Xiaoming Wu, Zhide Guo, Qingbao Yang, Xuejun Wen
  • Patent number: 11975079
    Abstract: The present disclosure provides a truncated Evans Blue modified fibroblast activation protein inhibitor compound. The compound is formed by connecting truncated Evans Blue, a fibroblast activation protein inhibitor and a nuclide chelating group by means of connecting groups L1, L2, L3, L4 and X. The compound has the following structure shown in Formula (I), where R1 is a fibroblast activation protein inhibitor; L1 is lysine, glutamic acid, or a derivative structure thereof; L2 is —(CH2)n—, n is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O—, —NH—, —(CO)—, —NH(CO)—, or —(CO)—NH—; L3 is —(CH2)m—, m is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O— or —(CO)—; L4 is —(CH2)p—, p is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O—, —NH—, —(CO)—, —NH(CO)—, or —(CO)—NH—; X is selected from N, C, O, S, or and R2 is a nuclide chelating group.
    Type: Grant
    Filed: July 11, 2021
    Date of Patent: May 7, 2024
    Assignee: YANTAI LANNACHENG BIOTECHNOLOGY CO., LTD.
    Inventors: Xiaoyuan Chen, Pengfei Xu, Zhide Guo, Xiaoming Wu, Qingbao Yang, Tian He
  • Publication number: 20240131205
    Abstract: The present disclosure relates to the fields of nuclear medicine and molecular imaging, and specifically relates to a dual-targeting compound and a preparation method and application thereof. The dual-targeting compound has the following structure shown in Formula (I). The present disclosure also provides a dual-targeting compound capable of being labeled with a radionuclide, and the compound has the following structure shown in Formula (I-1) or Formula (I-2). The dual-targeting compound of the present disclosure has high affinity for an FAP target and an integrin ?v?3 target, can realize synergistic targeting of the FAP target and the integrin ?v?3 target in tumors, and has high uptake in tumors and long retention time in tumors.
    Type: Application
    Filed: December 9, 2022
    Publication date: April 25, 2024
    Inventors: Xiaoyuan CHEN, Pengfei XU, Xiaoming WU, Zhide GUO, Qingbao YANG, Xuejun WEN
  • Patent number: 11957767
    Abstract: The present disclosure provides a compound targeting prostate specific membrane antigen (PSMA), wherein the compound has the following structure shown in Formula (I); R1 is a compound structure targeting prostate specific membrane antigen; L1 is -(X)n-(CH2)m-(Y)q-, X and Y are independently selected from lysine, glutamic acid or a derivative structure containing lysine and glutamic acid, n is an integer from 0 to 12, m is an integer from 0 to 60, q is an integer from 0 to 12, and each CH2 may be individually substituted with —O—, —NH(CO)—, or —(CO)—NH—; L2 is -(CH2)p-, p is an integer from 0 to 30, and each CH2 may be individually substituted with —O—, —NH(CO)—, or —(CO)—NH—; and R2 is a nuclide chelating group. The present disclosure also provides a radiolabeled complex based on the structure of the compound.
    Type: Grant
    Filed: February 27, 2022
    Date of Patent: April 16, 2024
    Assignee: YANTAI LANNACHENG BIOTECHNOLOGY CO., LTD.
    Inventors: Xiaoyuan Chen, Pengfei Xu
  • Publication number: 20240091389
    Abstract: The present disclosure provides a compound targeting prostate specific membrane antigen (PSMA), wherein the compound has the following structure shown in Formula (I); R1 is a compound structure targeting prostate specific membrane antigen; L1 is —(X)n—(CH2)m—(Y)q—, X and Y are independently selected from lysine, glutamic acid or a derivative structure containing lysine and glutamic acid, n is an integer from 0 to 12, m is an integer from 0 to 60, q is an integer from 0 to 12, and each CH2 may be individually substituted with —O—, —NH(CO)—, or —(CO)—NH—; L2 is —(CH2)p—, p is an integer from 0 to 30, and each CH2 may be individually substituted with —O—, —NH(CO)—, or —(CO)—NH—; and R2 is a nuclide chelating group. The present disclosure also provides a radiolabeled complex based on the structure of the compound.
    Type: Application
    Filed: February 27, 2022
    Publication date: March 21, 2024
    Inventors: Xiaoyuan CHEN, Pengfei XU
  • Publication number: 20240044319
    Abstract: A hydrostatic radial piston unit of the cam-lobe type of construction including a shaft defining a rotational axis of the hydrostatic radial piston unit. The shaft extends with a front end region from a non-rotary, stationary rear casing to a front casing. Within the front casing a cylinder block is housed and fixed in a torque-proof connection to the front end region of the shaft. In the cylinder block radially reciprocating working pistons are disposed in radially oriented cylinder bores to and from which cylinder bores hydraulic fluid can be conducted by means of a distributor. The distributor is arranged rotationally fixed with respect to the front casing and rotationally free relative to the shaft. A circumferential cam-lobe surface with which the working pistons can interact, is formed integrally with the front casing on its radial inner side.
    Type: Application
    Filed: December 16, 2021
    Publication date: February 8, 2024
    Inventors: Chris SHRIVE, Yanjiang WAN, Xiaoyuan CHEN
  • Publication number: 20230390421
    Abstract: The present disclosure provides a truncated Evans Blue modified fibroblast activation protein inhibitor compound. The compound is formed by connecting truncated Evans Blue, a fibroblast activation protein inhibitor and a nuclide chelating group by means of connecting groups L1, L2, L3, L4 and X. The compound has the following structure shown in Formula (I), where R1 is a fibroblast activation protein inhibitor; L1 is lysine, glutamic acid, or a derivative structure thereof; L2 is —(CH2)n—, n is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O—, —NH—, —(CO)—, —NH(CO)—, or —(CO)—NH—; L3 is —(CH2)m—, m is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O— or —(CO)—; L4 is —(CH2)p—, p is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O—, —NH—, —(CO)—, —NH(CO)—, or —(CO)—NH—; X is selected from N, C, O, S, or and R2 is a nuclide chelating group.
    Type: Application
    Filed: July 11, 2021
    Publication date: December 7, 2023
    Inventors: Xiaoyuan CHEN, Pengfei XU, Zhide GUO, Xiaoming WU, Qingbao YANG, Tian HE
  • Patent number: 11466024
    Abstract: A bicyclic compound acting as a ROR? inhibitor. Provided are a compound of formula (I) or a pharmaceutically acceptable salt thereof, the compound having a structure as represented by formula (I-A) or formula (I-B). The provided compound of formula (I-A) or formula (I-B) or pharmaceutically acceptable salt thereof has good ROR? inhibitory activities, being expected to be used for treating diseases mediated by ROR? receptors in a mammal.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: October 11, 2022
    Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Medshine Discovery Inc.
    Inventors: Kevin X Chen, Kai Zhou, Yanxin Yu, Boyu Hu, Linghui Wu, Xiaoyuan Chen, Jiangfeng Lin, Haomin Chen, Xiangjian Wang, Xiquan Zhang, Xin Tian, Hongjiang Xu
  • Publication number: 20220017495
    Abstract: A compound of Formula (I) or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt, is disclosed. Compositions comprising the compound and methods of use are also disclosed. Those dimeric Evans Blue derivatives, denoted as N(tEB)2, reversibly bind two molecules of albumin via the two albumin binding regions of each NtEB in the dimer, resulting in significantly increased binding affinity to albumin and extended circulation half-life in vivo. Further, when the N(tEB)2 is conjugated to a peptide therapeutic, the in situ formation of the complex of N(tEB)2 with two albumin molecules resulted in increased resistance of the peptide therapeutic from proteolysis.
    Type: Application
    Filed: January 30, 2020
    Publication date: January 20, 2022
    Inventors: Xiaoyuan CHEN, Gang NIU, Lixin LANG, Rui TIAN, Dale O. KIESEWETTER
  • Patent number: 10981866
    Abstract: The present invention is directed to a compound of Formula III or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt: Formula III wherein the definitions of R1-R12 and L1-L4 are provided in the disclosure, wherein R13 is a chelating group comprising 177Lu, and wherein R14 is a peptide. The compounds of Formula I may be covalently bonded to a peptide via a linker to provide a compound of Formula III and thereby extend the half-life of the therapeutic compound. The invention is also directed to pharmaceutical compositions of the disclosed compounds, as well as their use in the diagnosis or treatment of diseases.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: April 20, 2021
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Xiaoyuan Chen, Orit Jacobson Weiss
  • Publication number: 20210008232
    Abstract: A compound of Formula (I) or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt wherein the definitions of R1-R13 and L1-L4 are provided in the disclosure, and wherein R14 is a group capable of binding to prostate-specific membrane antigen (PSMA).
    Type: Application
    Filed: February 22, 2019
    Publication date: January 14, 2021
    Inventors: Xiaoyuan Chen, Orit Jacobson Weiss
  • Publication number: 20200231543
    Abstract: The present invention is directed to a compound of Formula III or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt: Formula III wherein the definitions of R1-R12 and L1-L4 are provided in the disclosure, wherein R13 is a chelating group comprising 177Lu, and wherein R14 is a peptide. The compounds of Formula I may be covalently bonded to a peptide via a linker to provide a compound of Formula III and thereby extend the half-life of the therapeutic compound. The invention is also directed to pharmaceutical compositions of the disclosed compounds, as well as their use in the diagnosis or treatment of diseases.
    Type: Application
    Filed: October 3, 2017
    Publication date: July 23, 2020
    Inventors: Xiaoyuan Chen, Orit Jacobson Weiss
  • Publication number: 20200231597
    Abstract: A bicyclic compound acting as a ROR? inhibitor. Provided are a compound of formula (I) or a pharmaceutically acceptable salt thereof, the compound having a structure as represented by formula (I-A) or formula (I-B). The provided compound of formula (I-A) or formula (I-B) or pharmaceutically acceptable salt thereof has good ROR? inhibitory activities, being expected to be used for treating diseases mediated by ROR? receptors in a mammal.
    Type: Application
    Filed: July 27, 2018
    Publication date: July 23, 2020
    Applicants: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., MEDSHINE DISCOVERY INC.
    Inventors: Kevin X CHEN, Kai ZHOU, Yanxin YU, Boyu HU, Linghui WU, Xiaoyuan CHEN, Jiangfeng LIN, Haomin CHEN, Xiangjian WANG, Xiquan ZHANG, Xin TIAN, Hongjiang XU
  • Patent number: 10709790
    Abstract: The present invention is directed to a compound of Formula I or Formula II or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt: Formula I Formula II The compounds of Formula I may be covalently bonded to a therapeutic compound or fragment thereof to provide a compound of Formula II and thereby extend the half-life of the therapeutic compound. The invention is also directed to pharmaceutical compositions of the disclosed compounds, as well as their use in the diagnosis or treatment of diseases.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: July 14, 2020
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Xiaoyuan Chen, Lixin Lang, Gang Niu
  • Patent number: 10696631
    Abstract: The present invention is directed to a compound of Formula I or Formula III or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt: wherein the definitions R1-R13 and L1-L4 are provided in the disclosure, and wherein R14 is a peptide. The compounds of Formula I may be covalently bonded to a peptide via a linker to provide a compound of Formula III and thereby extend the half-life of the therapeutic compound. The invention is also directed to pharmaceutical compositions of the disclosed compounds, as well as their use in the diagnosis or treatment of diseases.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: June 30, 2020
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Xiaoyuan Chen, Orit Jacobson Weiss
  • Patent number: 10646591
    Abstract: Disclosed are imaging agents having the following Formula I: wherein F is a near infrared fluorophore, S is an enzymatically cleavable oligopeptide, Q is a fluorescence quencher molecule, and M is a moiety selected from the group consisting of PEG or derivative thereof and a targeting ligand, and wherein F, Q and M are linked to separate amino acids of the enzymatically cleavable oligopeptide. Compositions comprising such compounds, as well as methods of use, methods of identifying a cell or a population of cells in vivo expressing a protease of interest, and methods of treating a disease through imaging are also disclosed.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: May 12, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Xiaoyuan Chen, Seulki Lee, Lei Zhu
  • Patent number: 10469952
    Abstract: A loudspeaker comprises a housing, a vibration diaphragm, a voice coil assembly, a centering support piece and a magnetic circuit system, an opening is provided at the center of the vibration diaphragm, and the voice coil assembly is fixed at the opening and is suspended in the housing; the magnetic circuit system comprises a magnetic conductive yoke fixedly connected with the housing, a magnet at one side of the magnetic conductive yoke close to the voice coil assembly, and a washer at one side of the magnet away from the magnetic conductive yoke; and a holder for supporting the centering support piece is provided on the washer, and the centering support piece is bonded and fixed to the inner wall of the voice coil assembly. By utilizing the present invention, the height of the loudspeaker can be effectively reduced, and the acoustic performance of the product can be increased.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: November 5, 2019
    Assignee: GOERTEK INC.
    Inventors: Xiaoyuan Chen, Zhi Li
  • Publication number: 20190298824
    Abstract: The present disclosure concerns chemical conjugates having structures satisfying Formula I and methods of making and using these chemical conjugates. Also described are immunomodulatory compositions comprising the chemical conjugates and methods of using the chemical conjugates and/or immunomodulatory compositions thereof to induce an immune response in a subject.
    Type: Application
    Filed: May 4, 2017
    Publication date: October 3, 2019
    Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Xiaoyuan Chen, Guizhi Zhu
  • Publication number: 20190201537
    Abstract: The present invention is directed to a compound of Formula I or Formula II or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt: Formula I Formula II The compounds of Formula I may be covalently bonded to a therapeutic compound or fragment thereof to provide a compound of Formula II and thereby extend the half-life of the therapeutic compound. The invention is also directed to pharmaceutical compositions of the disclosed compounds, as well as their use in the diagnosis or treatment of diseases.
    Type: Application
    Filed: June 21, 2016
    Publication date: July 4, 2019
    Inventors: Xiaoyuan Chen, Lixin Lang, Gang Niu
  • Patent number: 10258701
    Abstract: Disclosed is a compound of formula (I): wherein L, R1-R5, A, B, M, and n are as defined in the specification, as well as a method of preparing the compound. Also disclosed are a method of blood-pool imaging in a mammal and a method of imaging a lymph node in a mammal, comprising use of the compound.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: April 16, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Xiaoyuan Chen, Lixin Lang, Gang Niu